Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-Line vs Second-Line AEDs Substitution in Drug-Resistant Epilepsy
NCT05697614Phase 4Unknown
- Sponsor
- Dr. Cipto Mangunkusumo Hospital
- Start
- Mar 2023
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of valproic acid, carbamazepine and phenytoin in epilepsy (2 arms), sponsored by Dr. Cipto Mangunkusumo Hospital. Primary endpoint: Proportion of Responders at 14 weeks. Status: unknown.
02
Drugs
valproic acidcarbamazepinephenytoin
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT05697614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05697614.